Abstract
Caveolin-1 is associated with worse oncological features among patients treated with radical nephroureterectomy for upper tract urothelial carcinoma (UTUC), but is not independently associated with oncological outcomes. Its clinical use could be explored in UTUC biopsy specimens for improving clinical staging and helping in decision-making regarding a kidney-sparing approach or neoadjuvant systemic treatment.
Original language | English (US) |
---|---|
Pages (from-to) | 97-103 |
Number of pages | 7 |
Journal | European Urology Focus |
Volume | 5 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2019 |
All Science Journal Classification (ASJC) codes
- Urology